

FINAL PROGRAM

**ON-SITE &
VIRTUAL**



**CELCC
2021**

**20th Central European
Lung Cancer Conference**

November 11 – 13, 2021
Parkhotel Schönbrunn
Vienna, Austria

© Wien Tourismus Christian Stember

www.celcc2021.at



Robert Pirker



Helmut Prosch

Dear colleagues,

On behalf of the Organizing Committee, we would like to welcome you at the 20th CENTRAL EUROPEAN LUNG CANCER CONFERENCE (CELCC 2021) which takes place November 11-13, 2021. The Conference is organized by the Central European Lung Cancer Association (CELCA) and is planned as a hybrid event offering both on-site and virtual participation. The onsite Conference takes place at Parkhotel Schönbrunn in Vienna under strict COVID-19 pre-cautions.

The Central European Lung Cancer Conferences have a long tradition. The first Conference took place in 1992 in Prague. Since then, Conferences were held in Budapest, Gdansk, Ljubljana, Novi Sad, Prague, Riga and Vienna. CELCC 2021 will be both an educational as well as scientific event and will provide an update on recent developments in the diagnosis, treatment and management of lung cancer. Major topics will be latest advances in therapy with immune checkpoint inhibitors, immunotherapeutic combinations, novel targeted drugs, multimodality therapies and early detection of lung cancer.

CELCC 2021 offers an opportunity to finally meet again in person or virtually with colleagues and friends.

We thank you for your participation in the Conference.

Sincerely,

Robert Pirker and Helmut Prosch
Conference Presidents

Scientific Organizer

CELCA - Central European Lung Cancer Association

CELCA Board

Robert Pirker, President, Austria
Luboš Petruželka, 1st Vice-President, Czech Republic
Gyula Ostoros, 2nd Vice-President, Hungary
Thomas Brodowicz, Treasurer, Austria
Helmut Prosch, Secretary, Austria

Organizing Committee

Thomas Brodowicz, Austria
Karin Dieckmann, Austria
Martin Filipits, Austria
Mir Alireza Hoda, Austria
Rudolf Huber, Germany
Diego Kauffmann-Guerrero, Germany
Gyula Ostoros, Hungary
Luboš Petruželka, Czech Republic
Helmut Popper, Austria
Nevena Sečen, Serbia
Milada Zemanová, Czech Republic

Conference Management

Mondial

Mondial Congress & Events

celcc2021@mondial-congress.com

+43 1 58804 - 0 | Austria, Vienna

Virtual Conference Platform

You will receive your personal access code to the virtual conference platform a few days before the conference. The platform will remain open until Sunday, February 13, 2022. All on-demand scientific lectures will be accessible until then.

Accreditation for Continuing Medical Education

The 20th Central European Lung Cancer Conference, Vienna & online, Austria, 11/11/2021-13/11/2021 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 6 European CME credits (EC-MEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Certificate of Attendance

Participants obtain a certificate of attendance after the conference upon completing a short questionnaire. The questionnaire will be sent via email within a few days after the conference.

CELCC 2021 Best Paper Award

The author of the best abstract will be nominated for the CELCC 2021 Best Paper Award. The prize is endowed with EUR 500. The awardee will be presented in the Closing Ceremony on Saturday, November 13, 2021.

COVID-19 Measures: Entry into Austria

Persons who have been vaccinated with a vaccine approved by the European Medical Agency (EMA) or persons who have recovered and can present evidence of this may enter Austria without further restrictions.

For further information, please refer to this website:

https://www.oesterreich.gv.at/en/themen/coronavirus_in_oesterreich/pre-travel-clearance.html

COVID-19 Measures: Participation in the on-site Event

The conference takes place under strict COVID-19 pre-cautions according to governmental requirements. This means that you have to show a proof of vaccination or recovery from COVID-19 at the registration desk.

We thank our sponsors!

Gold Partner



Silver Partner



Thursday, 11 November 2021

17:00 - 19:00 On-site registration

18:00 - 19:30 Welcome reception

Friday, 12 November 2021

08:45 - 08:55 Welcome

Robert Pirker, Helmut Prosch

09:00 - 10:45 Early detection and molecular analyses of lung cancer

Chairs: Robert Pirker, Austria
Martin Svaton, Czech Republic

**Early detection of lung cancer in Central European countries:
Ongoing programs**
Helmut Prosch, Austria

Croatian national lung cancer screening program: An update
Ivana Kuhtic, Croatia

Molecular analyses of lung cancer: Current state-of-the-art
Ales Ryska, Czech Republic

Liquid biopsy in lung cancer: Is it standard practice?
Martin Filipits, Austria

**Small cell lung carcinoma:
Impact of new sub-typing on therapeutic options**
Helmut Popper, Austria

11:15 - 11:45 Industry-sponsored Satellite Symposium

Friday, 12 November 2021

12:00 - 12:30 8th Petr Zatloukal Memorial Lecture

Chairs: Milada Zemanova, Czech Republic
Robert Pirker, Austria

The impact of the Covid-19 pandemic on lung cancer care in Central European countries
Peter Berzinec, Slovakia

14:00 - 15:30 Combined modality therapy of operable NSCLC

Chairs: Rudolf Huber, Germany
Martin Filipits, Austria

Adjuvant systemic therapy in resected NSCLC
Robert Pirker, Austria

Pre-operative therapy in operable NSCLC
Lubos Petruzela, Czech Republic

Radiotherapy in operable NSCLC
Karin Dieckmann, Austria

**Adjuvant versus pre-operative therapy of operable NSCLC:
A surgeon's view**
Mir Alireza Hoda, Austria

Friday, 12 November 2021

16:00 - 17:30

Preferred papers

Chairs: Nevena Secen, Serbia
Milada Zemanova, Czech Republic

Harm reduction by heated tobacco, electronic cigarettes and oral nicotine products: not for the population

Manfred Neuberger, Austria

Nivolumab in the treatment of non-squamous non-small cell lung cancer in 2nd and higher line in real clinical practice: the Czech registry TULUNG

Jan Spacek, Czech Republic; Zemanová M, Zemanová P, Kultán J, Fischer O, Havel L, Drosslerová M, Krejčí D, Opálka P, Hrnčiarik M, Svatoň M, Pesek M, Jakubíková L, Skříčková J, Koubková L, Bílek O, Brožová L, Hejduk K, Šťastný M, Petruželka L

Do inflammatory parameters and anti-inflammatory comedication affect PD-L1 expression?

Martin Svaton, Czech Republic; Drosslerova M, Fischer O, Hrciarik M, Marel M, Venclíček O, Zuna P, Blazek J

Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): An international, real-world analysis

Maximilian Hochmair, Austria; Illini O, Fabikan H, Weinlinger C, Tufman A, Swalduz A, Lamberg K, Hashemi S, Huemer F, Vikström A, Wermke M, Absenger G, Addeo A, Banerji S, Calles A, Clarke S, Di Maio M, Durand A, Duruisseaux M, Itchins M, Kääräinen O, Krenn F, Laack E, De Langen A, Mohorcic K, Pall G, Passaro A, Prager G, Rittmeyer A, Rothenstein J, Schumacher M, Wöll E, Valipour A

Adenosine A_{2A} and dopamine D₂ GPCR heteromers in neuroendocrine lung carcinoids

Milena Cavic, Serbia; Moreno E, Velinovic M, Bukumiric Z, Krivokuca A, Stojic J, Canela E, Casado V

EGFR-mutant lung adenocarcinoma that transformed to small cell lung cancer - case report

Gabriela Chowaniecova, Slovakia; Ondruš D, Doláková L, Kočalková A, Košťuriaková G, Plank L, Farkašová A, Sekerešová M, Juskanič D, Beržinec P

Abstracts are available on the website www.celcc2021.at

Saturday, 13 November 2021

08:00 - 08:45 Chinese-Central European Lung Cancer Session

Chairs: Christian Manegold, Germany
Robert Pirker, Austria

Development of a prediction model of hyperprogressive disease after immune checkpoint inhibitor treatment in advanced lung cancer
Shuhui Cao, Shanghai Chest Hospital & Shanghai Jiao Tong University, Shanghai, China

ctDNA detection in perioperative NSCLC: current horizons and future perspectives
Kezhong Chen, Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China

09:00 - 10:30 Therapy of advanced lung cancer

Chairs: Lubos Petruzalka, Czech Republic
Rudolf Huber, Germany

Rare driver mutations and novel targeted drugs in advanced NSCLC
Diego Kauffmann-Guerrero, Germany

Immune checkpoint inhibitor combinations in advanced NSCLC
Gyula Ostoros, Hungary

Immune checkpoint inhibitors in locally advanced NSCLC
Jana Skrickova, Czech Republic

Therapeutic advances in SCLC
Nevena Secen, Serbia

11:00 - 11:45 Industry-sponsored Satellite Symposium

Saturday, 13 November 2021

12:00 - 13:15 **Imaging in lung cancer - What I always wanted to know**

Chairs: Gyula Ostoros, Hungary
Helmut Prosch, Austria

PET/CT - Indications and limitations
Lucian Beer, Austria

Diagnosis of equivocal lesions (adrenal glands, liver, bone)
Anna Kerpel Fronius, Hungary

Management of pulmonary nodules
Rudolf Huber, Germany

14:00 - 15:00 **Chinese-Central European Lung Cancer Panel Discussion**

Moderators: Baohui Han, China
Caicun Zhou, China
Christian Manegold, Germany
Robert Pirker, Austria

Chinese Panelists:

Jianchun Duan, Chinese Academy of Medical Sciences, Beijing
Jisheng Li, Qilu Hospital of Shandong University, China
Ling Peng, Zhejiang Provincial Peoples' Hospital, Hangzhou
Xiaohong Wu, Sir Run Run Shaw Hospital, Hangzhou
Lingyun Zhang, The First Hospital of China Medical University, Shenyang
Yongchang Zhang, Hunan Cancer Hospital, Changsha,
Xin Zhang, Shanghai Zhongshan Hospital, Pulmologist, China

European Panelists:
Karin Dieckmann, Austria
Rudolf Huber, Germany
Thomas Klikovits, Austria

Gyula Ostoros, Hungary
Lubos Petruzelka, Czech
Republic Helmut Popper, Austria
Helmut Prosch, Austria

15:05 - 15:15 **Closing remarks**

Robert Pirker, Helmut Prosch

Friday, 12 November 2021

11:15 - 11:45 **Industry-sponsored Satellite Symposium Boehringer Ingelheim**

Updated evidence on sequential EGFR TKI approach in
NSCLC treatment
Maximilian Hochmair

Saturday, 13 November 2021

11:00 - 11:45 **Industry-sponsored Satellite Symposium AstraZeneca
Advances in Early Stage NSCLC**

Lung Cancer Screening: Who will benefit most?
Helmut Prosch

ADAURA - The role of adjuvant EGFR TKIs in early stage NSCLC
Romana Wass

Discussion

www.celcc2021.at

Imprint: Media owner: Central European Lung Cancer Association (CELCA); printed in Austria
Photo credits: © Wien Tourismus, Christian Stemper